CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 23, 2005--The Immune Response Corporation (Nasdaq:IMNR), a biopharmaceutical company dedicated to becoming a leading immune-based therapy company in HIV and multiple sclerosis (MS), today announced that it has received notice from The Nasdaq Stock Market, Inc. that the Company’s shares will be delisted from the Nasdaq Capital Market effective at the open of business on Friday, November 25, 2005, based upon the Company’s failure to satisfy the $2,500,000 shareholders’ equity and $1.00 bid price requirements for continued listing.
